These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 201408)

  • 41. In vitro responses of peripheral blood and spleen lymphoid cells to mitogens and antigens in childhood Hodgkin's disease.
    Tan CT; de Sousa M; Tan R; Hansen JA; Good RA
    Cancer Res; 1978 Apr; 38(4):886-93. PubMed ID: 346206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ferritin on the surface of lymphocytes in Hodgkin's disease patients. A possible blocking substance removed by levamisole.
    Moroz C; Lahat N; Biniaminov M; Ramot B
    Clin Exp Immunol; 1977 Jul; 29(1):30-5. PubMed ID: 891036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.
    Fisher RI; Bostick-Bruton F
    J Immunol; 1982 Oct; 129(4):1770-4. PubMed ID: 6980949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease. Their relationship to immune function.
    Spinozzi F; Velardi A; Rambotti P; Losito A; Zampi I; Cernetti C; Gerli R; Martelli MF; Grignani F
    J Clin Lab Immunol; 1983 Oct; 12(2):87-92. PubMed ID: 6644793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of levamisole on E rosette inhibition by serum of malnourished children.
    Salimonu LS
    Biomed Pharmacother; 1983; 37(6):276-80. PubMed ID: 6200157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological markers of peripheral blood and lymph node lymphocytes in Hodgkin's disease.
    González M; Hernández F; San Miguel JF; Moraleda JM; Caballero MD; López Borrasca A
    Neoplasma; 1985; 32(2):191-8. PubMed ID: 4000308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Binding of soluble immune complexes in serum of patients with Hodgkin's disease to tissue cultures derived from the tumor.
    Long JC; Hall CL; Brown CA; Stamatos C; Weitzman SA; Carey K
    N Engl J Med; 1977 Aug; 297(6):295-9. PubMed ID: 559938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interference of levamisole with inhibition of E-rosette formation by Hodgkin's disease and systemic lupus erythematosus cytotoxic sera.
    Del Giacco GS; Tognella S; Leone AL; Locci F; Cornaglia P; Sangiuolo A; Grifoni V
    Blood; 1979 May; 53(5):1002-6. PubMed ID: 435634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of E rosette forming activity of human lymphocytes by rosette inhibiting factor (RIF) ann rosette restoring factor (RRF).
    Skibiński G; Zwoliński J; Wieczorek Z
    Arch Immunol Ther Exp (Warsz); 1979; 27(4):475-80. PubMed ID: 117784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subpopulations of human T lymphocytes. XIV. Abnormality of T-cell locomotion and of distribution of subpopulations of T and B lymphocytes in peripheral blood and spleen from children with untreated Hodgkin's disease.
    Gupta S; Tan C
    Clin Immunol Immunopathol; 1980 Feb; 15(2):133-43. PubMed ID: 6965467
    [No Abstract]   [Full Text] [Related]  

  • 53. T and B-RFC inhibiting factor in plasma from patients with active Hodgkin's disease.
    Ezdinli EZ; Simonson KL; Simonson LG; Wasser LP
    Cancer; 1979 Jul; 44(1):106-11. PubMed ID: 313239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The in vitro effect of a calf thymus extract (thymostimulin) on the immunologic parameters of patients with untreated Hodgkin's disease.
    Martelli MF; Velardi A; Rambotti P; Cernetti C; Bracaglia AM; Ballatori E; Davis S
    Cancer; 1982 Jan; 49(2):245-50. PubMed ID: 7053826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fc gamma receptors on lymphocytes from normal donors and patients with lymphoproliferative diseases. Influence of incubation conditions.
    Smit JW; van der Giessen M; Halie MR
    Acta Haematol; 1983; 70(2):108-18. PubMed ID: 6223479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Reed-Sternberg cell/lymphocyte rosette. I. Properties of rosettes formed between Hodgkin's cell lines and allogeneic lymphocytes.
    Flavell DJ; Wright DH
    Br J Cancer; 1989 Feb; 59(2):165-73. PubMed ID: 2495015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rosette and blastogenesis inhibition by plasma from Hodgkin's disease and other malignancies. Positive correlation in State I and II Hodgkin's disease.
    Sinclair T; Ezdinli EZ; Boonlayangoor P; Wasser LP; Han T
    Cancer; 1983 Jan; 51(2):238-44. PubMed ID: 6336976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphocyte subpopulations of lymph nodes and spleens in Hodgkin's disease.
    Pinkus GS; Barbuto D; Said JW; Churchill WH
    Cancer; 1978 Sep; 42(3):1270-9. PubMed ID: 308838
    [No Abstract]   [Full Text] [Related]  

  • 59. [Evaluation of the immunological status of patients with Hodgkin's disease].
    Rambotti P; Velardi A; Spinozzi F; Aversa F; Falini B
    Ann Sclavo; 1978; 20(3):225-38. PubMed ID: 310660
    [No Abstract]   [Full Text] [Related]  

  • 60. [The spleen and Hodgkin's disease].
    Athanasiu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1977; 29(4):207-306. PubMed ID: 22909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.